Protease-activated Receptor-1 Deficiency Protects Against Streptozotocin-induced Diabetic Nephropathy in Mice

Overview

Journal Sci Rep

Specialty Science

Date 2016 Sep 14

PMID 27618774

Citations 20

Authors

Maaike Waasdorp

JanWillem Duitman

Sandrine Florquin

C Arnold Spek

Affiliations

Soon will be listed here.

Abstract

Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and extracellular matrix production, thereby driving fibrotic disease. Considering the key role of mesangial proliferation and extracellular matrix production during DN, PAR-1 may in fact potentiate diabetes-induced kidney injury. To determine the net effect of PAR-1 in DN, streptozotocin-induced DN was studied in wild type and PAR-1 deficient mice. Subsequent mechanistic insight was obtained by assessing profibrotic responses of mesangial and tubular epithelial cells in vitro, following PAR-1 stimulation and inhibition. Despite having similar glucose levels, PAR-1 deficient mice developed less kidney damage after induction of diabetes, as evidenced by diminished proteinuria, plasma cystatin C levels, expansion of the mesangial area, and tubular atrophy. In vitro, PAR-1 signaling in mesangial cells led to increased proliferation and expression of matrix proteins fibronectin and collagen IV. Conversely, a reduction in both proliferation and fibronectin deposition was observed in diabetic PAR-1 deficient mice. Overall, we show that PAR-1 plays an important role in the development of DN and PAR-1 might therefore be an attractive therapeutic target to pursue in DN.

Citing Articles

PARticularly Forceful: PAR1 Drives Glomerular Mesangial Cell Contractility.

Waller A, Muralidharan K, Kerlin B Function (Oxf). 2024; 5(6).

PMID: 39293813 PMC: 11577620. DOI: 10.1093/function/zqae044.

Unveiling the Role of PAR 1: A Crucial Link with Inflammation in Diabetic Subjects with COVID-19.

Singh R, Singh V, Ahmad M, Pasricha C, Kumari P, Singh T Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675414 PMC: 11055094. DOI: 10.3390/ph17040454.

Proteomics of CKD progression in the chronic renal insufficiency cohort.

Dubin R, Deo R, Ren Y, Wang J, Zheng Z, Shou H Nat Commun. 2023; 14(1):6340.

PMID: 37816758 PMC: 10564759. DOI: 10.1038/s41467-023-41642-7.

Protease-Activated Receptor 1-Mediated Damage of Podocytes in Diabetic Nephropathy.

Bohovyk R, Khedr S, Levchenko V, Stefanenko M, Semenikhina M, Kravtsova O Diabetes. 2023; 72(12):1795-1808.

PMID: 37722138 PMC: 10658073. DOI: 10.2337/db23-0032.

Podocyte protease activated receptor 1 stimulation in mice produces focal segmental glomerulosclerosis mirroring human disease signaling events.

May C, Chesor M, Hunter S, Hayes B, Barr R, Roberts T Kidney Int. 2023; 104(2):265-278.

PMID: 36940798 PMC: 7616342. DOI: 10.1016/j.kint.2023.02.031.

References

Yoon H, Radulovic M, Wu J, Blaber S, Blaber M, Fehlings M . Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 2013; 127(2):283-98. PMC: 4097186. DOI: 10.1111/jnc.12293. View

Cattaneo F, Guerra G, Parisi M, De Marinis M, Tafuri D, Cinelli M . Cell-surface receptors transactivation mediated by g protein-coupled receptors. Int J Mol Sci. 2014; 15(11):19700-28. PMC: 4264134. DOI: 10.3390/ijms151119700. View

Duitman J, Ruela-de-Sousa R, Shi K, de Boer O, Borensztajn K, Florquin S . Protease activated receptor-1 deficiency diminishes bleomycin-induced skin fibrosis. Mol Med. 2014; 20:410-6. PMC: 4212012. DOI: 10.2119/molmed.2014.00027. View

Burch M, Ballinger M, Yang S, Getachew R, Itman C, Loveland K . Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. J Biol Chem. 2010; 285(35):26798-26805. PMC: 2930678. DOI: 10.1074/jbc.M109.092767. View

Isermann B, Vinnikov I, Madhusudhan T, Herzog S, Kashif M, Blautzik J . Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007; 13(11):1349-58. DOI: 10.1038/nm1667. View

Macfarlane S, Seatter M, Kanke T, HUNTER G, Plevin R . Proteinase-activated receptors. Pharmacol Rev. 2001; 53(2):245-82. View

Li J, Wu H, Zhang L, Zhu B, Dong B . Heparin and related substances for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2010; (9):CD005631. DOI: 10.1002/14651858.CD005631.pub2. View

Jaffre F, Friedman A, Hu Z, Mackman N, Blaxall B . β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012; 125(24):2993-3003. PMC: 3386307. DOI: 10.1161/CIRCULATIONAHA.111.066787. View

Carr M . Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15(1):44-54. DOI: 10.1016/s1056-8727(00)00132-x. View

10.

Coughlin S . Protease-activated receptors in vascular biology. Thromb Haemost. 2001; 86(1):298-307. View

11.

Knecht W, Cottrell G, Amadesi S, Mohlin J, Skaregarde A, Gedda K . Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem. 2007; 282(36):26089-100. DOI: 10.1074/jbc.M703840200. View

12.

Cunningham M, Rondeau E, Chen X, Coughlin S, Holdsworth S, Tipping P . Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 2000; 191(3):455-62. PMC: 2195821. DOI: 10.1084/jem.191.3.455. View

13.

Wang Y, Chen J, Chen L, Tay Y, Rangan G, Harris D . Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997; 8(10):1537-45. DOI: 10.1681/ASN.V8101537. View

14.

Howell D, Laurent G, Chambers R . Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans. 2002; 30(2):211-6. DOI: 10.1042/. View

15.

Zhang Y . Non-Smad pathways in TGF-beta signaling. Cell Res. 2008; 19(1):128-39. PMC: 2635127. DOI: 10.1038/cr.2008.328. View

16.

Anil Kumar P, Welsh G, Saleem M, Menon R . Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front Endocrinol (Lausanne). 2014; 5:151. PMC: 4174857. DOI: 10.3389/fendo.2014.00151. View

17.

Gao L, Chao L, Chao J . A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2009; 316(3):376-89. PMC: 2812679. DOI: 10.1016/j.yexcr.2009.10.022. View

18.

Little P . GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical Gαq protein signalling pathways. Life Sci. 2013; 92(20-21):951-6. DOI: 10.1016/j.lfs.2013.03.017. View

19.

Vesey D, Cheung C, Kruger W, Poronnik P, Gobe G, Johnson D . Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. Kidney Int. 2005; 67(4):1315-29. DOI: 10.1111/j.1523-1755.2005.00209.x. View

20.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View